Ignite Creation Date:
2024-05-05 @ 4:40 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00295672
Status:
COMPLETED
Last Update Posted:
2009-07-28
First Post:
2006-02-23
Brief Title:
Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC
Sponsor:
University Hospital Brest
Organization:
University Hospital Brest
Study Overview
Official Title:
Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy With Cisplatin-docetaxel in Patients With Locally Advanced Non-small-cell Lung Cancer A Multicenter Phase II Trial
Status:
COMPLETED
Status Verified Date:
2009-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VINCR
Brief Summary:
Our aim is to conducted a multicenter phase II trial of the cisplatin-oral vinorelbine -radiotherapy combination after induction chemotherapy with cisplatin-docetaxel in patient with NSCLC Oral vinorelbine will be used in the present study rather than the intravenous form because 1- Previous investigations have demonstrated that oral vinorelbine is as effective as the intravenous form in the treatment of NSCLC 2 - We think that the use of oral agents in CT will reduce some disagreements provoked by intravenous injections stress infections hemorrhage displacement at the hospital and cost of CT
Detailed Description:
About one-third of patients with non-small-cell lung cancer NSCLC have inoperable locally advanced stage III disease at diagnosis The most satisfactory treatment for patients with locally advanced NSCLC is combination chemotherapy-radiotherapy CT-RT However the optimal interval between irradiation and chemotherapy as well as the most effective chemotherapy protocol remains to be defined
Our aim is to conducted a multicenter phase II trial of the cisplatin-oral vinorelbine -radiotherapy combination after induction chemotherapy with cisplatin-docetaxel in patient with NSCLC Oral vinorelbine will be used in the present study rather than the intravenous form because 1- Previous investigations have demonstrated that oral vinorelbine is as effective as the intravenous form in the treatment of NSCLC 2 - We think that the use of oral agents in CT will reduce some disagreements provoked by intravenous injections stress infections hemorrhage displacement at the hospital and cost of CT
Patients will be enrolled in the study by members of GFPC a French cooperative group on thoracic oncology The main eligibility criteria are histologically or cytologically documented inoperable stage IIIA N2 or IIIB NSCLC previously untreated absence of malignant pleural effusion performance status PS 1 and patient life expectancy of at least 12 weeks Induction chemotherapy will comprise two cycles of cisplatin 80mgm2 and docetaxel 75mgm2 given on D1 and D22 Concomitant CT-RT will start on D57 Radiotherapy will occur from D57 until D99 2 Gyday 5 daysweek total dose is 66 Gy Cisplatin 80mgm2 will be given on D57 first day of irradiation and D78 Oral vinorelbine 40 mgm2 will be administered on D57 D64 D78 and D85 The main endpoint is the objective response rate The tumor response will be assessed first at the end of induction chemotherapy and again 4 weeks after concurrent CT-RT Patients who will progress after induction chemotherapy will leave the study Those with stable disease or a tumor response will receive the CT-RT combination Tolerability time until progression duration of response and proportion of survival at 1 2 and 3 years represent a secondary endpoints The study will be achieved according to the French legislation and guidelines for biomedical research involving human subjects
Our aim is to conducted a multicenter phase II trial of the cisplatin-oral vinorelbine -radiotherapy combination after induction chemotherapy with cisplatin-docetaxel in patient with NSCLC Oral vinorelbine will be used in the present study rather than the intravenous form because 1- Previous investigations have demonstrated that oral vinorelbine is as effective as the intravenous form in the treatment of NSCLC 2 - We think that the use of oral agents in CT will reduce some disagreements provoked by intravenous injections stress infections hemorrhage displacement at the hospital and cost of CT
Patients will be enrolled in the study by members of GFPC a French cooperative group on thoracic oncology The main eligibility criteria are histologically or cytologically documented inoperable stage IIIA N2 or IIIB NSCLC previously untreated absence of malignant pleural effusion performance status PS 1 and patient life expectancy of at least 12 weeks Induction chemotherapy will comprise two cycles of cisplatin 80mgm2 and docetaxel 75mgm2 given on D1 and D22 Concomitant CT-RT will start on D57 Radiotherapy will occur from D57 until D99 2 Gyday 5 daysweek total dose is 66 Gy Cisplatin 80mgm2 will be given on D57 first day of irradiation and D78 Oral vinorelbine 40 mgm2 will be administered on D57 D64 D78 and D85 The main endpoint is the objective response rate The tumor response will be assessed first at the end of induction chemotherapy and again 4 weeks after concurrent CT-RT Patients who will progress after induction chemotherapy will leave the study Those with stable disease or a tumor response will receive the CT-RT combination Tolerability time until progression duration of response and proportion of survival at 1 2 and 3 years represent a secondary endpoints The study will be achieved according to the French legislation and guidelines for biomedical research involving human subjects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| VINCR - GFPC 05-03 | None | None | None |